Cognition and neurocognition: Effects of risperidone, olanzapine, and haloperidol

Mark J. Sergi, Michael F. Green, Clifford Widmark, Christopher Reist, Stephen Erhart, David L. Braff, Kimmy S. Kee, Stephen R. Marder, Jim Mintz

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

Objective: This study examined the short-term effects of first- and second-generation antipsychotic medications on social cognition and basic cognition. Method: One hundred patients with schizophrenia or schizoaffective disorder participated in an 8 week, double-blind study of risperidone, olanzapine, and haloperidol. Participants were administered multiple measures of social cognition, basic cognition, and clinical symptoms at baseline, the end of week 4, and the end of week 8. Seventy-three patients completed the baseline assessment and at least one other assessment. Data were analyzed with mixed-effects analyses of covariance. For data reduction, the social cognitive measures were clustered into a summary score, and the cognitive measures were clustered into two summary scores: general cognitive ability and processing speed. (The effects on thinking of risperidone and olanzapine can be found at NCT00108368, www.clinicaltrials.gov.) Results: There were no treatment-related differences on any of the three summary scores. Social cognition did not show within-group changes over time either by itself or after control for the cognitive clusters. One cognitive score (general cognitive ability) increased during the study period for all three medication groups. Conclusions: The present study included a rather thorough assessment of social cognition and did not find any evidence of between-group or within-group effects of antipsychotic medication on social cognition.

Original languageEnglish (US)
Pages (from-to)1585-1592
Number of pages8
JournalAmerican Journal of Psychiatry
Volume164
Issue number10
DOIs
StatePublished - Oct 2007
Externally publishedYes

Fingerprint

olanzapine
Risperidone
Haloperidol
Cognition
Aptitude
Antipsychotic Agents
Double-Blind Method
Psychotic Disorders
Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Cognition and neurocognition : Effects of risperidone, olanzapine, and haloperidol. / Sergi, Mark J.; Green, Michael F.; Widmark, Clifford; Reist, Christopher; Erhart, Stephen; Braff, David L.; Kee, Kimmy S.; Marder, Stephen R.; Mintz, Jim.

In: American Journal of Psychiatry, Vol. 164, No. 10, 10.2007, p. 1585-1592.

Research output: Contribution to journalArticle

Sergi, MJ, Green, MF, Widmark, C, Reist, C, Erhart, S, Braff, DL, Kee, KS, Marder, SR & Mintz, J 2007, 'Cognition and neurocognition: Effects of risperidone, olanzapine, and haloperidol', American Journal of Psychiatry, vol. 164, no. 10, pp. 1585-1592. https://doi.org/10.1176/appi.ajp.2007.06091515
Sergi, Mark J. ; Green, Michael F. ; Widmark, Clifford ; Reist, Christopher ; Erhart, Stephen ; Braff, David L. ; Kee, Kimmy S. ; Marder, Stephen R. ; Mintz, Jim. / Cognition and neurocognition : Effects of risperidone, olanzapine, and haloperidol. In: American Journal of Psychiatry. 2007 ; Vol. 164, No. 10. pp. 1585-1592.
@article{52e72955c72a4fd0b5143396e088a3b7,
title = "Cognition and neurocognition: Effects of risperidone, olanzapine, and haloperidol",
abstract = "Objective: This study examined the short-term effects of first- and second-generation antipsychotic medications on social cognition and basic cognition. Method: One hundred patients with schizophrenia or schizoaffective disorder participated in an 8 week, double-blind study of risperidone, olanzapine, and haloperidol. Participants were administered multiple measures of social cognition, basic cognition, and clinical symptoms at baseline, the end of week 4, and the end of week 8. Seventy-three patients completed the baseline assessment and at least one other assessment. Data were analyzed with mixed-effects analyses of covariance. For data reduction, the social cognitive measures were clustered into a summary score, and the cognitive measures were clustered into two summary scores: general cognitive ability and processing speed. (The effects on thinking of risperidone and olanzapine can be found at NCT00108368, www.clinicaltrials.gov.) Results: There were no treatment-related differences on any of the three summary scores. Social cognition did not show within-group changes over time either by itself or after control for the cognitive clusters. One cognitive score (general cognitive ability) increased during the study period for all three medication groups. Conclusions: The present study included a rather thorough assessment of social cognition and did not find any evidence of between-group or within-group effects of antipsychotic medication on social cognition.",
author = "Sergi, {Mark J.} and Green, {Michael F.} and Clifford Widmark and Christopher Reist and Stephen Erhart and Braff, {David L.} and Kee, {Kimmy S.} and Marder, {Stephen R.} and Jim Mintz",
year = "2007",
month = "10",
doi = "10.1176/appi.ajp.2007.06091515",
language = "English (US)",
volume = "164",
pages = "1585--1592",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "10",

}

TY - JOUR

T1 - Cognition and neurocognition

T2 - Effects of risperidone, olanzapine, and haloperidol

AU - Sergi, Mark J.

AU - Green, Michael F.

AU - Widmark, Clifford

AU - Reist, Christopher

AU - Erhart, Stephen

AU - Braff, David L.

AU - Kee, Kimmy S.

AU - Marder, Stephen R.

AU - Mintz, Jim

PY - 2007/10

Y1 - 2007/10

N2 - Objective: This study examined the short-term effects of first- and second-generation antipsychotic medications on social cognition and basic cognition. Method: One hundred patients with schizophrenia or schizoaffective disorder participated in an 8 week, double-blind study of risperidone, olanzapine, and haloperidol. Participants were administered multiple measures of social cognition, basic cognition, and clinical symptoms at baseline, the end of week 4, and the end of week 8. Seventy-three patients completed the baseline assessment and at least one other assessment. Data were analyzed with mixed-effects analyses of covariance. For data reduction, the social cognitive measures were clustered into a summary score, and the cognitive measures were clustered into two summary scores: general cognitive ability and processing speed. (The effects on thinking of risperidone and olanzapine can be found at NCT00108368, www.clinicaltrials.gov.) Results: There were no treatment-related differences on any of the three summary scores. Social cognition did not show within-group changes over time either by itself or after control for the cognitive clusters. One cognitive score (general cognitive ability) increased during the study period for all three medication groups. Conclusions: The present study included a rather thorough assessment of social cognition and did not find any evidence of between-group or within-group effects of antipsychotic medication on social cognition.

AB - Objective: This study examined the short-term effects of first- and second-generation antipsychotic medications on social cognition and basic cognition. Method: One hundred patients with schizophrenia or schizoaffective disorder participated in an 8 week, double-blind study of risperidone, olanzapine, and haloperidol. Participants were administered multiple measures of social cognition, basic cognition, and clinical symptoms at baseline, the end of week 4, and the end of week 8. Seventy-three patients completed the baseline assessment and at least one other assessment. Data were analyzed with mixed-effects analyses of covariance. For data reduction, the social cognitive measures were clustered into a summary score, and the cognitive measures were clustered into two summary scores: general cognitive ability and processing speed. (The effects on thinking of risperidone and olanzapine can be found at NCT00108368, www.clinicaltrials.gov.) Results: There were no treatment-related differences on any of the three summary scores. Social cognition did not show within-group changes over time either by itself or after control for the cognitive clusters. One cognitive score (general cognitive ability) increased during the study period for all three medication groups. Conclusions: The present study included a rather thorough assessment of social cognition and did not find any evidence of between-group or within-group effects of antipsychotic medication on social cognition.

UR - http://www.scopus.com/inward/record.url?scp=35748959361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35748959361&partnerID=8YFLogxK

U2 - 10.1176/appi.ajp.2007.06091515

DO - 10.1176/appi.ajp.2007.06091515

M3 - Article

C2 - 17898351

AN - SCOPUS:35748959361

VL - 164

SP - 1585

EP - 1592

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 10

ER -